Decrease of Urinary Nerve Growth Factor but Not Brain-Derived Neurotrophic Factor in Patients with Interstitial Cystitis/Bladder Pain Syndrome Treated with Hyaluronic Acid

Yuan-Hong Jiang¹, Hsin-Tzu Liu¹,², Hann-Chorng Kuo*¹

¹Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan, ²Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan

Abstract

Aims: To investigate urinary nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) levels in interstitial cystitis/bladder pain syndrome (IC/BPS) patients after hyaluronic acid (HA) therapy.

Methods: Thirty-three patients with IC/BPS were prospectively studied; a group of 45 age-matched healthy subjects served as controls. All IC/BPS patients received nine intravesical HA instillations during the 6-month treatment regimen. Urine samples were collected for measuring urinary NGF and BDNF levels at baseline and 2 weeks after the last HA treatment. The clinical parameters including visual analog scale (VAS) of pain, daily frequency nocturia episodes, functional bladder capacity (FBC) and global response assessment (GRA) were recorded. Urinary NGF and BDNF levels were compared between IC/BPS patients and controls at baseline and after HA treatment.

Results: Urinary NGF, NGF/Cr, BDNF, and BDNF/Cr levels were significantly higher in IC/BPS patients compared to controls. Both NGF and NGF/Cr levels significantly decreased after HA treatment. Urinary NGF and NGF/Cr levels significantly decreased in the responders with a VAS pain reduction by 2 (both p < 0.05) and the GRA improved by 2 (both p < 0.05), but not in non-responders. Urinary BDNF and BDNF/Cr did not decrease in responders or non-responders after HA therapy.

Conclusions: Urinary NGF, but not BDNF, levels decreased significantly after HA therapy; both of these factors remained higher than in controls even after HA treatment. HA had a beneficial effect on IC/BPS, but it was limited. The reduction of urinary NGF levels was significant in responders, with a reduction of pain and improved GRA.

Introduction

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic inflammatory disorder of the urinary bladder characterized by bladder pain associated with frequency, urgency, nocturia, and sterile urine. The aetiology of IC/BPS remains unclear and is thought to be multifactorial, including defective or dysfunctional bladder urothelium, neurogenic inflammation, activation of mast cells, autoimmunity, and occult infection [1,2,3]. In IC/BPS, disruption of the urothelial barrier initiates a cascade of events in the bladder, leading to symptoms and disease [4]. Specifically, epithelial dysfunction leads to the migration of urinary solutes, in particular, potassium that depolarizes nerves and muscles and causes tissue injury. Suburothelial and neurogenic inflammation in IC/BPS inhibits normal basal cell proliferation and affects apical urothelial function, forming a vicious cycle provoking and maintaining inflammatory reactions in the bladder [1,5].

Glycosaminoglycan (GAG) is a part of the normal bladder epithelium as a chemical barrier and protects the bladder mucosa from bacterial adhesion and penetration by toxic substances in the urine [6]. In IC/BPS patients, this GAG layer is thought to be partially defective, causing a defect in the permeability barrier of the urothelium [7]. Infiltrated urine would induce submucosal inflammation, stimulating sensory nerve fibers and causing frequency and pain [8], although the reason why the GAG layer becomes defective has been unknown. In addition, the urinary GAG profile and hyaluronic acid (HA) levels significantly correlated with IC/BPS severity [9]. A few uncontrolled or non-interventional studies of intravesical HA treatment of IC/BPS patients showed symptomatic improvement over a broad range between 30% and 83% of patients [10,11,12,13,14,15,16]. However, these studies lacked solid evidence from multi-centre, randomized controlled trials to show the long-term superiority and the anti-inflammatory effect of intravesical HA treatment for IC/BPS.
Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are the most studied neurotrophins in the bladder, governing innervation during development, growth, and injury [17,19]. NGF and BDNF are expressed in the urothelium and bladder smooth muscle, influencing lower urinary tract symptoms of overactive bladder (OAB) and IC/BPS [17,18,19]. Urinary neurotrophins can be used as biomarkers to improve the accuracy of diagnosing OAB and IC/BPS and to monitor the effectiveness of treatment [19,20].

Previous study has shown increased urinary chemokines and cytokines (including NGF) had different expression among control, ulcerative and non-ulcerative IC/BPS. All patients with characteristics of IC/BPS were excluded, and all of the eligible patients in this study were non-ulcerative IC/BPS. All patients with characteristics of IC/BPS were previously treated conservatively with heparin and/or pentosan polysulfate and were refractory to treatment. A total of 45 people without urological disease or lower urinary tract symptoms were recruited from patients and hospital employees and served as the control subjects.

All IC/BPS patients received nine times of intravesical HA instillations (50ml, 0.08% sodium hyaluronate) (Bioniche, Canada) over the course of a 6-month period, including four weekly intravesical instillations of 40 mg of HA followed by 5 monthly HA instillations. Urine samples were collected for measuring urinary NGF and BDNF levels at baseline (immediately before the first treatment) and 2 weeks after the last HA treatment.

Clinically, patients were assessed for pain using 10-point visual analogue scale (VAS). Patients were requested to measure their bladder pain elicited at full bladder from 0 [no pain at all] to 10 (extremely painful) at baseline and after treatment. In addition, a three-day voiding diary to record daily frequency and nocturia episodes, and functional bladder capacity (FBC, the maximum volume voided in the voiding diary) were also recorded. The treatment outcome was also assessed using the global response assessment (GRA) [22,24]. Patients were requested to rate their bladder symptoms compared to baseline on a 7-point centered assessment (GRA) [23,24]. Urinary symptoms compared to baseline on a 7-point centered assessment (GRA) [23,24]. Urinary symptoms were measured using the 7-point centered assessment (GRA) [23,24]. Patients were requested to rate their urinary symptoms on a 7-point centered assessment (GRA) [23,24].

The present study was approved by the institutional Review Board and Ethics Committee of Buddhist Tzu Chi General Hospital. Each patient was informed about the study rationale and procedures, and written informed consent was obtained before the treatment.

**Urinary NGF and BDNF Measurement**

Urinary NGF and BDNF levels were measured using the enzyme-linked immunosorbent assay (ELISA) method [25]. Voided urine was put on ice immediately and transferred to the laboratory for preparation. The samples were centrifuged at 3,000 rpm for 10 minutes at 4°C. The supernatant was separated into aliquots in 1.5-ml tubes and preserved in a freezer at −80°C. At the same time, 3 mL of urine was taken to measure the urinary creatinine level.

The NGF and BDNF concentrations were determined using the Enzyme ImmunoAssay System (Promega, Madison, WI, USA), with a precise and highly sensitive ELISA kit, which had a minimum sensitivity of 7.8 pg/ml. Assays were performed according to the manufacturer’s instructions. Briefly, NGF and BDNF levels were determined using an antibody sandwich format in 96-well plates. Each well was initially coated with 100 µL of anti-NGF/BDNF polyclonal antibody and incubated overnight at 4°C, followed by 1-h incubation with blocking buffer to prevent nonspecific binding. Either 100 µl of urine or 100 µl of NGF/BDNF standard (0–250 pg/mL) was added to each well followed by incubation for 6 hours at room temperature with shaking. Then, the plate was washed, anti-NGF/BDNF monoclonal antibody was added, and the plate was incubated at 4°C for 14–18 hours. After the plate had been washed again, the amount of bound monoclonal antibody was detected using IgG-horse-radish peroxidase conjugated antibody as a tertiary reactant. The unbound conjugate was removed by washing, and the plate was then incubated with 100 µL of TMB (3,3’5,5’ tetramethyl benzidine) substrate solution for 10 minutes at room temperature. Hydrochloric acid (1 N, 100 µL) was added to terminate the reactions. The colour change was measured with a Synergy HT Microplate Reader (Bio-Tek Instruments) at 450 nm. The amounts of NGF and BDNF in each urine sample were determined from a standard curve. All samples were run in triplicate, and the values were averaged. Total urinary NGF and BDNF levels were normalized by urinary creatinine concentration (NGF/Cr and BDNF/Cr levels). ELISA assay for urinary NGF and BDNF was performed at baseline, and after completed HA treatment.

**Statistical Analysis**

Normalized total urinary NGF/Cr and BDNF/Cr levels were expressed as means ± standard deviations. Unpaired Student’s t and Mann-Whitney tests were used for statistical analysis between groups when considering parametric and nonparametric data, respectively. Pearson correlation was used to evaluate the associations between the variations in urinary NGF/Cr and BDNF/Cr levels. A P value < 0.05 was considered to indicate statistical significance; all tests were two-tailed. All statistical analyses were performed with the statistical package SPSS for Windows (Version 12, SPSS, Chicago, IL, USA).

**Results**

The mean age was 46.9 ± 14.0 years (range, 16–61 years) among the 33 IC/BPS patients and 43.9 ± 14.0 years (range, 19–58 years) among the 45 controls (p = 0.77). There were five male patients each among the IC/BPS patients and controls.

At baseline, urinary NGF, NGF/Cr, BDNF and BDNF/Cr levels were significantly higher in IC/BPS patients compared to the controls (Table 1). After the 6-month intravesical HA treatment regimen for IC/BPS patients, urinary NGF and
NGF/Cr levels both decreased significantly while urinary BDNF and BDNF/Cr levels did not. In addition, clinical assessments including VAS, GRA and FBC all significantly improved after treatment. Although the decrease of urinary NGF and NGF/Cr levels and the improvement of clinical parameters were noted after HA treatment, urinary NGF, NGF/Cr and BDNF levels in HA treated IC/BPS patients were still significantly higher than in controls, except for urinary BDNF/Cr levels (p = 0.08).

After intravesical HA treatment, among the 33 IC/BPS patients, 14 patients (42.4%) experienced a pain VAS reduction of ≥ 2 (pain responders), 7 patients (21.2%) experienced a GRA reduction of ≥ 2 (GRA responders), and 13 patients (39.4%) experienced an FBC increase of ≥ 50% (FBC responders) (Table 2). Urinary NGF and NGF/Cr levels were significantly decreased in pain responders and in GRA responders, but not in non-responders. However, there was no significant change in urinary NGF/Cr level, in either FBC responders or non-responders. Within either pain, GRA, and FBC responders or non-responders, there was no significant change of urinary BDNF or BDNF/Cr level after intravesical HA treatment.

Discussion

Urinary NGF and BDNF levels in IC/BPS patients were significantly higher than in the control subjects [22]. In IC/BPS patients after intravesical HA treatment, urinary NGF levels and clinical assessments including the pain VAS, GRA and FBC all significantly decreased compared to baseline, suggesting that HA treatment has an anti-inflammatory effect. However, the urinary NGF or BDNF levels after HA treatment were still significantly higher than in controls, except for urinary BDNF/Cr levels (p = 0.08).

Table 1. Comparison of the clinical characteristics and urinary nerve growth factor (NGF), NGF/creatinine (NGF/Cr), brain-derived neurotrophic factor (BDNF), and BDNF/Cr levels between controls and IC/BPS patients.

|                      | Controls (N = 45) | Baseline IC/BPS patients (N = 33) | Post-HA treatment IC/BPS patients (N = 33) | p value* | p value# | p value$ |
|----------------------|------------------|----------------------------------|------------------------------------------|---------|---------|---------|
| Urinary NGF (pg/ml)  | 2.25±0.91        | 92.4±24.9                        | 34.2±10.6                                | 0.04    | <0.01   | <0.01   |
| Urinary NGF/Cr (pg/mg)| 0.37±0.13       | 31.1±12.0                        | 8.13±2.81                               | 0.02    | <0.01   | <0.01   |
| Urinary BDNF (pg/ml) | 9.57±5.37        | 107.5±40.8                       | 64.1±21.0                               | 0.68    | <0.01   | <0.01   |
| Urinary BDNF/Cr (pg/mg)| 4.82±2.45     | 23.8±7.70                        | 17.2±7.37                               | 0.55    | <0.01   | 0.08    |
| VAS                  | 3.12±2.47        | 1.79±2.07                        | <0.01                                   |
| GRA                  | 1.09±0.84        | 1.85±0.94                        | <0.01                                   |
| FBC (ml)             | 171±92.5         | 229±118                          | <0.01                                   |

*: p value between baseline and post-HA treatment data in IC/BPS patients.
#: p value between the baseline data in controls and IC/BPS patients.
$: p value between the data in controls and the post-HA treatment data in IC/BPS patients.

VAS: visual analogue score, GRA: global response assessment, FBC: functional bladder capacity.

Table 2. Comparison of urinary NGF/Cr and BDNF/Cr levels in clinical responders and non-responders after intravesical hyaluronic acid treatment in IC/BPS patients.

|                      | Urinary NGF/Cr (pg/mg) | Urinary BDNF/Cr (pg/mg) |
|----------------------|------------------------|-------------------------|
|                      | Baseline | HA treatment | P value | Baseline | HA treatment | P value |
| VAS                  |          |             |         |          |             |         |
| Responder * (n = 14) | 34.1±14.5 | 9.41±5.21   | 0.03    | 14.9±10.5 | 9.96±3.39   | 0.58    |
| Non-responder (n = 19) | 28.9±18.2 | 7.18±3.15   | 0.21    | 29.8±10.8 | 22.6±12.6  | 0.33    |
| P value              | 0.52     | 0.73        |         | 0.12     | 0.70        |         |
| GRA                  |          |             |         |          |             |         |
| Responder # (n = 7)  | 45.2±25.7 | 4.53±2.15   | 0.04    | 28.9±22.2 | 10.7±5.04  | 0.92    |
| Non-responder (n = 26) | 27.3±13.7 | 9.10±3.52  | 0.13    | 22.6±8.21 | 19.0±9.28  | 0.55    |
| P value              | 0.40     | 0.79        |         | 0.68     | 0.38        |         |
| FBC                  |          |             |         |          |             |         |
| Responder $ (n = 13) | 25.7±14.3 | 4.34±1.23   | 0.14    | 24.0±11.5 | 6.76±2.35  | 0.29    |
| Non-responder (n = 20) | 34.6±17.7 | 10.6±4.54  | 0.06    | 23.6±10.4 | 24.0±11.9  | 0.98    |
| P value              | 0.87     | 0.91        |         | 0.78     | 0.71        |         |

*: Responder in VAS: decrease of ≥ 2 scales.
#: Responder in GRA: increase of ≥ 2 scales.
$: Responder in FBC: increase of ≥ 50% of baseline.

Data are expressed as mean ± standard deviation.
doi:10.1371/journal.pone.0091609.t001
doi:10.1371/journal.pone.0091609.t002
higher than in the controls, suggesting chronic inflammation in IC/BPS bladders could not be totally eradicated after one 6-month treatment course of HA.

HA is considered a good candidate for GAG layer substitution to provide a protective barrier for impaired urothelium in IC/BPS patients. HA prevents direct exposure of the urothelium to urine, bacterial adherence and the possibility of infection [26]. The restoration of urothelial barrier function should help prevent the vicious cycle of suburothelial inflammation and relieve bladder pain symptoms in IC/BPS patients.

NGF and BDNF are the most investigated neurotrophins in the lower urinary tract, especially in the bladder; they represent feasible diagnostic and treatment targets to improve bladder function [17,18]. Elevated levels of circulating NGF might also increase the excitability or susceptibility of sensory receptors in suburothelial nerve fibers such as purinergic receptors P2X3 and transient receptors potential vanilloid receptor subfamily 1 (TRPV1) through intrinsic enhancement, causing the bladder to become more excitable, which in turn leads to symptoms of IC/BPS [27]. Endogenous NGF seems to contribute to lower urinary tract dysfunction through regulation of neural function, as well as inflammation and pain [25]. NGF applied in the bladder results in changes of bladder function, including bladder hyperreflexia, while affecting the visceral pain sensation by inducing hyperalgesia. It is proposed that these effects resemble pathologies associated with bladder overactivity and inflammatory pain, such as OAB.

Figure 1. The changes of urinary levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). The urinary levels of NGF (pg/ml) and BDNF (pg/ml) were compared between baseline and after 6-month treatment of HA (6M) in responders and non-responders based on (A) a visual analogue scale (VAS, for pain) decrease of ≥ 2, (B) global response assessment (GRA) increase of ≥ 2 and (C) functional bladder capacity (FBC) increase of ≥ 50%. Data are expressed as means ± standard deviations.
doi:10.1371/journal.pone.0091609.g001
and IC/BPS [18]. BDNF is the most abundant neurotrophin although less investigated, and little is known about the role of BDNF in bladder function both in normal and pathological conditions [17,20]. Following chronic bladder inflammation and spinal cord injury, the synthesis of BDNF in the bladder is strongly increased [25,29]. In addition, BDNF sequestration improved bladder function in rats with chronic cystitis [29].

In IC/BPS patients, NGF levels in both urine and serum increased, suggesting chronic inflammation is involved in the pathogenesis of the disease [22]. After cystoscopy histodestinension treatment, a decrease in urinary NGF level was associated with greater pain reduction and a successful treatment response in IC/BPS patients [30]. Additionally, trigonal injection of botulinum toxin A improves IC/BPS symptoms, and significantly reduces urinary NGF and BDNF levels, even though the reduction is transient [31]. In our study, the reduction of urinary NGF level was significant in pain responders (decreased pain) and in those with GRA improvement. Altogether, both NGF and BDNF in the urine reflect the inflammatory conditions in patients with IC/BPS and indicate the clinical therapeutic effects of treatment.

In a rat model of cyclophosphamide-induced cystitis, HA was an effective treatment for bladder overactivity through the involvement of NGF signalling [32]. In this study, urinary NGF, but not BDNF, levels in IC/BPS patients decreased after intravesical HA treatment. However, urinary NGF, NGF/Cr, and BDNF levels in these HA treated patients were significantly higher than in control subjects. Urinary NGF and NGF/Cr levels decreased significantly in pain and GRA responders. Interestingly, we did not find a significant decrease of urinary BDNF or BDNF/Cr in such responders or non-responders after HA therapy. There are two possible explanations for this phenomenon. The first is that HA had a limited anti-inflammatory effect on IC/BPS, causing significant decreases in only urinary NGF and NGF/Cr, but not BDNF or BDNF/Cr (although the levels decreased, the reduction was not statistically significant). Further management including repeated intravesical HA instillation or intravesical botulinum toxin A injection is necessary to eradicate the chronic suburothelial inflammation of IC/BPS. Additionally, all the percentage of the responders in VAS, GRA, or FBC did not exceed 50% after HA treatment. Secondly, changes in these two neurotrophin levels after HA treatment might reflect their different roles of chronic inflammation in IC/BPS.

In a previous prospective randomized study, two different HA regimens to treat IC/BPS provided similar significant improvements in symptoms scores and quality of life index during the 6-month treatment period [33]. Nonetheless, there is remarkably little objective laboratory evidence to indicate the therapeutic effects of HA on IC/BPS. The present study shows a significant change in urinary NGF level after HA treatment, which not only shows the therapeutic role of HA in the treatment of IC/BPS, but also indicates that urinary NGF could be considered a potential biomarker to evaluate the clinical response to IC/BPS treatment.

This study has some limitations. Although this was a prospective study, the sample size was small and from a single centre. In addition, since there was no placebo arm in this study, the effect of intravesical placebo instillation in these IC/BPS patients could not be determined. The collection of urine samples for measuring neurotrophic factors was not standardized to voided urine volume. Both the room temperature and the time from sample collection to laboratory might affect the protein measurements. More specific and standardized procedures for the collection of urinary neurotrophic factors are required in the future work.

**Conclusion**

Urinary NGF, but not BDNF, levels decreased significantly after intravesical HA therapy for IC/BPS, but these two factors in HA treated patients were still higher than in the control subjects. The therapeutic effects of HA on IC/BPS manifested but were limited. The reduction of urinary NGF level was significant in pain responders (decreased pain) and in those with GRA improvement.

**Author Contributions**

Conceived and designed the experiments: HCK. Performed the experiments: HTL. Analyzed the data: YHJ. Contributed reagents/materials/analysis tools: HCK. Wrote the paper: YHJ HCK.

**References**

1. Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, et al. (2009) Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 16: 597–615.
2. Nickel JC (2004) Interstitial cystitis: a chronic pelvic pain syndrome. Med Clin North Am 88: 467–481, xii.
3. Shie JH, Kuo HC (2011) Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108: E136–141.
4. Parsons CL (2007) The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 69: 9–16.
5. Kuo HC (2012) Novel treatments of interstitial cystitis/bladder pain syndrome based on pathophysiology. Clinical Investigation 2: 1085–1100.
6. Hurst RE, Rhodes SW, Adamson PB, Parsons CL, Roy JB (1987) Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface. J Urol 138: 433–437.
7. Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, et al. (1996) A deficit of cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 108: E136–141.
8. Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145: 732–735.
9. Lokeswar VB, Selzer MG, Usosken AJ, Estrella V, Gomez MJ, et al. (2006) Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol 176: 1001–1007.
10. Morales A, Emerson I, Nickel JC, Lunde M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156: 45–48.
11. Porta D, Campus G, Tudino D, Valdes E, Vespa A, et al. (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59: 26–29.
12. Kallestrup EB, Jorgensen SS, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 39: 143–147.
13. Daha LK, Riedl CR, Lazar D, Hoebregger G, Pfuger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47: 393–397; discussion 397.
14. Riedl CR, Engelhardt PF, Daha KL, Morakia N, Pfuger H (2008) Hyaluronic treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 19: 717–721.
15. Daha LK, Riedl CR, Lazar D, Simak R, Pfuger H (2008) Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol Nephrol 42: 369–372.
16. Engelhardt PF, Morakia N, Daha LK, Estebauer B, Riedl CR (2011) Long-term results of intravesical hyaluronic acid therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 22: 401–403.
17. Frias B, Lopes T, Pinto R, Cruz F, Cruz CD (2011) Neurotrophins in the lower urinary tract: becoming of age. Curr Neuropharmacol 9: 535–538.
18. Ochonicki P, Cruz CD, Yoshimura N, Michel MC (2011) Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 30: 1227–1241.
19. Ochonicki P, Cruz CD, Yoshimura N, Cruz F (2012) Neurotrophins as regulators of urinary bladder function. Nat Rev Urol 9: 628–637.
20. Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, et al. (2013) Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 189: 959–965.
21. Trasy P, Kulling C, Trasy V, Nirmal J, Chancellor M, et al. (2012) Urinary chemoattractants as noninvasive predictors of ulcerative interstitial cystitis. J Urol 187: 2243–2248.
22. Liu HT, Kuo HC (2012) Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One 7: e44687.
23. Chung SD, Kuo YC, Kuo HC (2012) Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician 15: 197–202.
24. Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, et al. (2005) Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 65: 654–658.
25. Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161: 273–284.
26. Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME (2007) Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 51: 1534–1540; discussion 1540–1531.
27. Steers WD, Tuttle JB (2006) Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3: 101–110.
28. Pezet S, Malcangio M, McMahon SB (2002) BDNF: a neuropeptide in nociceptive pathways? Brain Res Brain Res Rev 40: 240–249.
29. Pinto R, Frias B, Allen S, Dawbarn D, McMahon SB, et al. (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166: 907–916.
30. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 104: 1476–1481.
31. Pinto R, Lopes T, Frias B, Silva A, Silva JA, et al. (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58: 360–365.
32. Ho DR, Chen CS, Lin WY, Chang PJ, Huang YC (2011) Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis. Int J Urol 18: 525–531.
33. Lai MC, Kuo YC, Kuo HC (2013) Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol 20: 203–207.